Table 3.

Clinicopathological features of hepatocellular carcinomas with positive YAP1 expression (N = 624)

		N (%)	p-value
Sex	Male[518] vs. Female[106]	16(3) vs. 4 (4)	0.715
Age (yr)	≤55[324] vs. >55[300]	9(3) vs. 11 (4)	0.681
Size (cm)	≤5.0[379] vs. >5.0[235]	12(3) vs. 8 (3)	0.872
Multiplicity	Single[449] vs. Multiple[169]	11(2) vs. 9 (5)	0.072
Vascular invasion	Absent[330] vs. Present[286]	10(3) vs. 10 (3)	0.745
Large vessel invasion	Absent[578] vs. Present[37]	18(3) vs. 2 (5)	0.446
pT stage (AJCC 7th)	pT1–2[486] vs. pT3–4[138]	16(3) vs. 4 (3)	0.982
ES nuclear grade	1–2[300] vs. 3–4[313]	4(1) vs. 15 (5)	0.014*
Preoperative treatment	Done[261] vs. Not done[315]	13(5) vs. 6 (2)	0.114
Serum AFP (ng/ml)	≤32[309] vs. >32[289]	4(1) vs. 14 (5)	0.011*
Cell type	Hepatic[539] vs. Non-hepatic[61]	17(3) vs. 2 (3)	0.958
Histologic pattern	Trabecular/acinar[487] vs. Compact[113]	12(2) vs. 7 (6)	0.041*
Desmoplastic stroma	Absent[462] vs. Present[113]	9(2) vs. 9 (8)	<0.001*
Expression of CK19	Negative[523] vs. Positive[101]	10(2) vs. 10 (10)	<0.001*
Etiology of CLD	Viral[557] vs. Non-viral[36]	19(3) vs. 0 (0)	0.621

*p-value <0.05; ES nuclear grade, Edmonson-Steiner nuclear grade; CLD chronic liver disease